Cell & Gene Collaborative Blog

81. ARW's C&G+RNA Manufacturing Must-Reads (Capture The Flag Edition!) 6/16/2022

    Every two weeks, I compile the manufacturing-centric articles and industry updates most worthy of your time into an unconventional newsletter format and send them out via email. On June 16th, we celebrated “Recess At Work Day,” which is dedicated to building workplace team spirit and innovation. In this edition of Must-Reads sent on June 16th, I attempt to rekindle the joys of recess with a “live” play-by-play narrative (by A.) and color commentary (by R.) on an industry-wide game of “Capture the Flag.” However, this is not your typical game of Capture the Flag…

82. The “Renaissance” Approach To Cell & Gene Therapy Manufacturing 6/13/2022

    We’re all familiar with the concept of the “Renaissance Man/Woman". In the context of the CGT space, however, can there be such a thing as a “Renaissance Company”? My conversation with Poseida Therapeutics' CEO Mark Gergen proves that there can be and establishes why a generalist mindset is necessary to bring the CGT manufacturing paradigm to maturity.

83. ARW's C&G (+RNA!) Manufacturing Must-Reads (Dracula Edition!) 6/3/2022

    Day-in and day-out, I write, read, listen to, and watch as much content as I can about C&G therapy manufacturing, in particular, and/or other C&G industry-related topics that you should at least be aware of in the manufacturing facility. Every two weeks, I compile the articles and industry updates I think are most worthy of your time into an unconventional newsletter format (below) and send them out via email. But inboxes can be shifty places. (Cue George Carlin on “Losing Things.”)

84. Can USP, NIST, & NIIMBL Conquer The Biggest AAV Quality Challenge? 5/18/2022

    As the CGT industry continues struggling to sufficiently characterize its AAV, USP's Fouad Atouf and I unpacked the ins-and-outs of this ongoing USP, NIST, and NIIMBL AAV quality initiative — as well as the CGT industry’s greatest needs from such a collaboration.

85. ARW's C&G Manufacturing Must-Reads (The Simpsons Edition!) 5/9/2022

    Day-in and day-out, I write, read, listen to, and watch as much content as I can about C&G therapy manufacturing, in particular, and/or other C&G industry-related topics that you should at least be aware of in the manufacturing facility. Every two weeks, I compile the articles and industry updates I think are most worthy of your time into an unconventional newsletter format (below) and send them out via email. But inboxes can be shifty places. (Cue George Carlin on “Losing Things.”)

86. ARW's Cell & Gene Manufacturing Must-Reads (Classic Literature Edition!) 4/25/2022

     Every two weeks, I compile the articles and industry updates I think are most worthy of your time into an unconventional newsletter format and send them out via email. For this April 21 edition, I decided to play with the “Thank You For Libraries Day” theme. Below, each section of articles includes a quote and several not-so-subtle references to classic works of literature you’d likely find in any of the world's most glorious libraries.

87. Time Well-Spent: Embracing Opportunity Costs In Gene Therapy Manufacturing 4/11/2022

    It goes without saying that “taking time” to get a solid process in place is a best practice. But what I particularly appreciated about my conversation with Tenaya CTO's Kee-Hong Kim was how his own experiences and perspectives helped define what exactly “time well spent” means in the CGT development process. 

88. ARW's C&G Manufacturing Must-Reads (GIANT RODENT! Edition) 4/8/2022

    Day-in and day-out, I write, read, listen to, and watch as much content as I can about C&G therapy manufacturing, in particular, and/or other C&G industry-related topics that you should at least be aware of in the manufacturing facility. Every two weeks, I compile the articles and industry updates I think are most worthy of your time into an unconventional newsletter format (below) and send them out via email. But inboxes can be shifty places. (Cue George Carlin on “Losing Things.”)

89. Show Me The Money! A Closer Look At COGS In Gene Therapy Manufacturing 4/6/2022

    It’s almost inevitable that any conversation about manufacturing will be filled with references to “Time” and “Money,” and my conversation with Tenaya CTO, Kee-Hong Kim was no exception. But while these words can be dangerously vague, Kim’s experience added some valuable context into how he approaches these two resources in his role — starting first with “money.”

90. Your C&G Manufacturing Must-Reads (Philly Cheesesteak Edition!) 3/25/2022

    Here’s a “permanent” copy of my C&G Manufacturing Must-Reads newsletter that was delivered on March 24, which just happened to be National Cheesesteak Day. Ergo, this is the “Philly Cheesesteak edition” of your manufacturing must-reads, in honor of our many friends in “Cellicon Valley”/Philadelphia.